Innate Pharma SA Sponsored ADR ( (IPHA) ) has released its Q2 earnings. Here is a breakdown of the information Innate Pharma SA Sponsored ADR presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing innovative approaches such as monoclonal antibodies, NK Cell Engagers, and antibody-drug conjugates. The company is based in Marseille, France, and is publicly traded on Euronext Paris and Nasdaq.
In its latest earnings report for the first half of 2025, Innate Pharma reported a net loss of €21.3 million, a slight improvement from the €24.8 million loss in the same period in 2024. The company highlighted a decrease in operational revenues and a reduction in research and development expenses.
Key financial metrics revealed a decrease in operational revenues to €4.9 million from €12.3 million in the previous year, mainly due to lower collaboration and license agreement revenues. Operating expenses were reduced to €30.3 million from €38.7 million, with R&D expenses accounting for a significant portion. The company also reported a net financial gain of €4.1 million, attributed to favorable currency exchange variations.
Looking ahead, Innate Pharma’s future activities depend on successful R&D efforts, market acceptance of its drug candidates, timely additional funding, and competition from other biotech and pharmaceutical companies. The company plans to continue financing through collaboration agreements, equity instruments, and loans.